Frazier Life Sciences

Venture capital firm

Portfolio

1 total

Attovia Therapeutics

Co-Investors

6

Deep Track Capital · 1 shared EcoR1 Capital · 1 shared Goldman Sachs Alternatives · 1 shared Illumina Ventures · 1 shared Sanofi Ventures · 1 shared venBio Partners · 1 shared

Latest Pulse

Pulse coverage →

Jul 29, 2026Goldman-Backed Attovia Seeks $212.5M in Biotech IPOAttovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.→
Jul 22, 2026Crystalys Raises $130M to Push Gout Drug Through Phase 3Crystalys Therapeutics raised a $130 million Series B led by Frazier Life Sciences to fund global Phase 3 trials of dotinurad, an oral gout drug already approved in five Asian markets, less than a year after a $205 million Series A.→

Suggest a correction